These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 32979674)
1. Temporal trends in first-line outpatient anticoagulation treatment for cancer-associated venous thromboembolism. Delate T; Charlu M; Zhu S; Pai A; Clark NP; Witt DM; King JM; King JB Thromb Res; 2020 Dec; 196():367-370. PubMed ID: 32979674 [TBL] [Abstract][Full Text] [Related]
2. Outpatient use of low molecular weight heparin monotherapy for first-line treatment of venous thromboembolism in advanced cancer. Delate T; Witt DM; Ritzwoller D; Weeks JC; Kushi L; Hornbrook MC; Aiello Bowles EJ; Schrag D Oncologist; 2012; 17(3):419-27. PubMed ID: 22334451 [TBL] [Abstract][Full Text] [Related]
3. Anticoagulant use in patients with cancer associated venous thromboembolism: a retrospective cohort study. Rahme E; Feugère G; Sirois C; Weicker S; Ramos E Thromb Res; 2013 Mar; 131(3):210-7. PubMed ID: 23290095 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of US prescription patterns: Are treatment guidelines for cancer-associated venous thromboembolism being followed? Khorana AA; Yannicelli D; McCrae KR; Milentijevic D; Crivera C; Nelson WW; Schein JR Thromb Res; 2016 Sep; 145():51-3. PubMed ID: 27485998 [TBL] [Abstract][Full Text] [Related]
5. Continuation of low-molecular-weight heparin treatment for cancer-related venous thromboembolism: a prospective cohort study in daily clinical practice. van der Wall SJ; Klok FA; den Exter PL; Barrios D; Morillo R; Cannegieter SC; Jimenez D; Huisman MV J Thromb Haemost; 2017 Jan; 15(1):74-79. PubMed ID: 28012224 [TBL] [Abstract][Full Text] [Related]
6. Assessment of venous thromboembolism treatment in patients with cancer on low molecular weight heparin, warfarin, and the direct oral anticoagulants. Uppuluri EM; Burke KR; Haaf CM; Shapiro NL J Oncol Pharm Pract; 2019 Mar; 25(2):261-268. PubMed ID: 28942721 [TBL] [Abstract][Full Text] [Related]
7. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Akl EA; Kahale L; Neumann I; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H Cochrane Database Syst Rev; 2014 Jun; (6):CD006649. PubMed ID: 24945634 [TBL] [Abstract][Full Text] [Related]
8. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Akl EA; Vasireddi SR; Gunukula S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H Cochrane Database Syst Rev; 2011 Jun; (6):CD006649. PubMed ID: 21678360 [TBL] [Abstract][Full Text] [Related]
9. Practice patterns surrounding referral to a specialty venous thromboembolism (VTE) clinic: a retrospective review. Landry S; Ip S; Shiu J; Bungard TJ J Thromb Thrombolysis; 2022 Jan; 53(1):176-181. PubMed ID: 34146236 [TBL] [Abstract][Full Text] [Related]
10. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Akl EA; Vasireddi SR; Gunukula S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H Cochrane Database Syst Rev; 2011 Feb; (2):CD006649. PubMed ID: 21328285 [TBL] [Abstract][Full Text] [Related]
11. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Akl EA; Vasireddi SR; Gunukula S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H Cochrane Database Syst Rev; 2011 Apr; (4):CD006649. PubMed ID: 21491395 [TBL] [Abstract][Full Text] [Related]
12. Trends in Anticoagulant Utilization and Clinical Outcomes for Cancer-Associated Thrombosis: A Multicenter Cohort Study in Thailand's Upper-Middle-Income Country Setting. Kengkla K; Nathisuwan S; Sripakdee W; Saelue P; Sengnoo K; Sookprasert A; Subongkot S JCO Glob Oncol; 2024 Feb; 10():e2300353. PubMed ID: 38422463 [TBL] [Abstract][Full Text] [Related]
13. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Di Nisio M; Porreca E; Otten HM; Rutjes AW Cochrane Database Syst Rev; 2014 Aug; (8):CD008500. PubMed ID: 25171736 [TBL] [Abstract][Full Text] [Related]
14. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Akl EA; Rohilla S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann HJ Cochrane Database Syst Rev; 2008 Jan; (1):CD006649. PubMed ID: 18254108 [TBL] [Abstract][Full Text] [Related]
15. DOAC compared to LMWH in the treatment of cancer related-venous thromboembolism: a systematic review and meta-analysis. Mai V; Tanguay VF; Guay CA; Bertoletti L; Magnan S; Turgeon AF; Lacasse Y; Lega JC; Provencher S J Thromb Thrombolysis; 2020 Oct; 50(3):661-667. PubMed ID: 32052314 [TBL] [Abstract][Full Text] [Related]
16. Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban Versus Low-molecular-weight Heparin and Warfarin in the Outpatient Setting. Deitelzweig S; Laliberté F; Crivera C; Germain G; Bookhart BK; Olson WH; Schein J; Lefebvre P Clin Ther; 2016 Aug; 38(8):1803-1816.e3. PubMed ID: 27491278 [TBL] [Abstract][Full Text] [Related]
17. Retrospective Review of Prescribing Patterns in Cancer-Associated Thrombosis: A Single Center Experience in Edmonton, Alberta, Canada. Kaliel H; Mior M; Quan S; Ghosh S; Wu C; Bungard TJ Clin Appl Thromb Hemost; 2021; 27():1076029620975489. PubMed ID: 33443455 [TBL] [Abstract][Full Text] [Related]
18. Survival outcomes with warfarin compared with direct oral anticoagulants in cancer-associated venous thromboembolism in the United States: A population-based cohort study. Khan AM; Chiasakul T; Redd R; Patell R; McCarthy EP; Neuberg D; Zwicker JI PLoS Med; 2022 May; 19(5):e1004012. PubMed ID: 35613184 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in Spain. Muñoz A; Gallardo E; Agnelli G; Crespo C; Forghani M; Arumi D; Fernández de Cabo S; Soto J J Med Econ; 2022; 25(1):840-847. PubMed ID: 35703036 [TBL] [Abstract][Full Text] [Related]
20. Healthcare resource utilization and costs associated with venous thromboembolism in cancer patients treated with anticoagulants. Streiff M; Milentijevic D; McCrae KR; Laliberté F; Lejeune D; Lefebvre P; Schein J; Khorana AA J Med Econ; 2019 Nov; 22(11):1134-1140. PubMed ID: 31106638 [No Abstract] [Full Text] [Related] [Next] [New Search]